Corticosteroid injection plus exercise versus exercise, beyond advice and a heel cup for patients with plantar fasciopathy:protocol for a randomised clinical superiority trial (the FIX-Heel trial) by Riel, Henrik et al.
 
  
 
Aalborg Universitet
Corticosteroid injection plus exercise versus exercise, beyond advice and a heel cup
for patients with plantar fasciopathy
protocol for a randomised clinical superiority trial (the FIX-Heel trial)
Riel, Henrik; Vicenzino, Bill; Olesen, Jens Lykkegaard; Jensen, Martin Bach; Ehlers, Lars
Holger; Rathleff, Michael Skovdal
Published in:
Trials
DOI (link to publication from Publisher):
10.1186/s13063-019-3977-0
Creative Commons License
CC BY 4.0
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Riel, H., Vicenzino, B., Olesen, J. L., Jensen, M. B., Ehlers, L. H., & Rathleff, M. S. (2020). Corticosteroid
injection plus exercise versus exercise, beyond advice and a heel cup for patients with plantar fasciopathy:
protocol for a randomised clinical superiority trial (the FIX-Heel trial). Trials, 21(1), [5].
https://doi.org/10.1186/s13063-019-3977-0
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
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Corticosteroid injection plus exercise versus
exercise, beyond advice and a heel cup for
patients with plantar fasciopathy: protocol
for a randomised clinical superiority trial
(the FIX-Heel trial)
Henrik Riel1*, Bill Vicenzino2, Jens Lykkegaard Olesen1, Martin Bach Jensen1, Lars Holger Ehlers3 and
Michael Skovdal Rathleff1,4,5
Abstract
Background: Plantar fasciopathy has a lifetime prevalence of 10%. Patients experience sharp pain under the heel,
often for several months or years. Multiple treatments are available, but no single treatment appears superior to the
others. A corticosteroid injection offers short-term pain relief but is no better than placebo in the longer term (> 8
weeks). Heavy-slow resistance training has shown potentially positive effects on long-term outcomes (> 3 months),
and combining exercises with an injection may prove to be superior to exercises alone. However, the effect of
heavy-slow resistance training compared with a simpler approach of patient advice (e.g., load management) and
insoles is currently unknown. This trial compares the efficacy of patient advice with patient advice plus heavy-slow
resistance training and with patient advice plus heavy-slow resistance training plus a corticosteroid injection in
improving the Foot Health Status Questionnaire pain score after 12 weeks in patients with plantar fasciopathy.
Methods: In this randomised superiority trial, we will recruit 180 patients with ultrasound-confirmed plantar
fasciopathy and randomly allocate them to one of three groups: (1) patient advice and an insole (n = 60); (2) patient
advice, an insole, and self-dosed heavy-slow resistance training consisting of heel raises (n = 60); or (3) patient
advice, an insole, heavy-slow resistance training, and an ultrasound-guided corticosteroid injection (n = 60). All
participants will be followed for 1 year, with the 12-week follow-up considered the primary endpoint. The primary
outcome is the Foot Health Status questionnaire pain domain score. Secondary outcomes include the remaining
three domains of the Foot Health Status Questionnaire, a 7-point Global Rating of Change, the Pain Self-Efficacy
Questionnaire, physical activity level, health-related quality of life measured by the EQ-5D-5L, and Patient
Acceptable Symptom State, which is the point at which participants feel no further need for treatment.
Additionally, a health economic evaluation of the treatments will be carried out.
Discussion: This trial will test if adding heavy-slow resistance training to fundamental patient advice and an insole
improves outcomes and if a corticosteroid injection adds even further to that effect in patients with plantar
fasciopathy.
Trial registration: ClinicalTrials.gov, NCT03804008. Prospectively registered on January 15, 2019.
Keywords: Plantar fasciopathy, Heavy-slow resistance training, Corticosteroid injection, Foot orthoses, Patient advice
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Background
One in ten persons will develop plantar fasciopathy (PF)
[1, 2]. The condition accounts for 8% of all running-
related injuries but is also common in the general popu-
lation [3–5]. A high running volume is associated with a
higher risk of developing PF, and despite a lack of pro-
spective studies to identify risk factors among non-
runners, a high body mass index is thought to be a risk
factor [6]. Pain is often worse during the first steps after
getting out of bed or during the first steps after periods
of non-weight-bearing [7].
PF was formerly known as ‘plantar fasciitis’ or ‘heel spur
syndrome’ and has historically been considered a self-
limiting condition in which 80% are expected to achieve
symptom-free status within 12months. This view of a self-
limiting condition has been challenged by research [1, 8–11].
Approximately half of patients referred to a specialised
secondary care clinic still experienced pain 10 years after
treatment [9], and 40% of patients in a randomised con-
trolled trial still had symptoms 2 years after plantar fascia-
specific stretching and wearing insoles [8]. Patients with PF
show greater levels of depression, stress, anxiety and kinesio-
phobia and experience limitations in both mobility and
health-related quality of life compared with pain-free individ-
uals [12–14]. Moreover, PF may be associated with several
days of sick leave. Davis et al. found that 6 of 105 patients
had taken as much as 3months off work [15], and we
recently found that 23% of patients in the workforce had
taken a median of 30 days off work due to their heel pain in
one study [16] and 20% had taken between 5 and 548 days
off work in another [17]. Thus, the consequences for both
patients and society are marked.
A systematic review and network meta-analysis com-
pared several commonly used treatment options for PF
[18]. Overall, they concluded that none of the investigated
treatments were superior to the others, but different treat-
ments may have different temporal profiles. Some are effi-
cacious in the short term (< 4 weeks), such as an injection
with corticosteroid, whereas others (e.g., exercises or orth-
oses are more efficacious in the longer term [> 12 weeks])
[18–22]. Heavy-slow resistance training (HSR) was not
included in the review, but it is generally known for a long-
term efficacy in the rehabilitation of both upper- and
lower-limb tendinopathies [23–25]. In PF, HSR has been
found to be superior to plantar fascia-specific stretching,
but only 6% achieve an acceptable symptom state within
12 weeks [16, 26]. This emphasises the need for additional
improvements to current care of these patients.
Combining HSR with a corticosteroid injection may
provide both short- and long-term pain relief for indi-
viduals with PF. We recently conducted a feasibility
study of the combination of these two treatments, which
supports running an efficacy trial. Patients’ rating of
acceptability, time to commencement of exercise after
the injection, compliance with exercise, recruitment rate,
and changes in foot-related health and function over time
supported this current proposed trial [27]. In theory, com-
bined treatments could supplement each other and give
both an immediate and long-term pain reduction.
Repeated corticosteroid injections and a combination
of stretching and foot-strengthening exercises have been
investigated before, but the combination of HSR and a
single corticosteroid injection is yet to be studied [28].
Previous studies in other tendinopathies only compared
the combined treatments with one of the treatments and
reported no differences [24, 29]. The limitation of these
studies is that it remains unknown if any of the treat-
ments have had some effect or no effect overall on the
condition, because the trials did not include a control
arm [24, 29]. We propose that a trial of combined interven-
tions versus one of the interventions requires a control
arm. A minimal intervention (control arm) consisting of pa-
tient advice, which reflects current general practitioner
(GP) practice (unpublished data), will enable a meaningful
comparison with more time-consuming and expensive
treatments, such as exercises and injections. If we do not fill
this knowledge gap, we might use costly and time-
consuming treatments without knowing the effect com-
pared with simpler treatment. To our knowledge, there is
no literature available on the cost-effectiveness of alterna-
tive treatments of PF [30]. Despite treatment costs for PF
possibly seeming relatively small compared with other more
expensive health technologies, the productivity costs to so-
ciety may be substantial in PF due to patients’ sick leave.
The present trial is the product of a series of preceding
studies conducted by our group in this patient popula-
tion in general practice. Interviews with GPs about the
management of PF showed a high heterogeneity wherein
some would give a steroid injection at first consultation,
some would prescribe exercises, and some would refer
to a physiotherapist (unpublished data). However, com-
monalities were to give patients advice on what they
could do to self-manage and an uncertainty about the
effectiveness of the many treatments available for PF. To
investigate if we could improve outcomes associated
with HSR, we compared a traditional pre-determined
HSR programme with a self-dosed programme to target
self-efficacy and increase the exercise dose received. We
found that both programmes were associated with simi-
lar improvements [16]. Following that randomised trial,
we investigated the feasibility of combining HSR with an
ultrasound-guided corticosteroid injection in the feasibil-
ity study described above as a final step before initiating
the present trial [27].
Objectives
The purpose of this trial is to investigate the efficacy of
fundamental patient advice and a heel cup (PA) versus
Riel et al. Trials            (2020) 21:5 Page 2 of 13
fundamental patient advice and a heel cup plus heavy-slow
resistance training (PAX) versus a combination of funda-
mental patient advice and a heel cup plus heavy-slow resist-
ance training and an ultrasound-guided corticosteroid
injection (PAXI) in improving the Foot Health Status Ques-
tionnaire pain domain score after 12 weeks in individuals
with PF.
Hypotheses
Hypothesis 1: The group receiving PAXI will be superior
to the group receiving PAX.
Hypothesis 2: The group receiving PAXI will be super-
ior to the group receiving PA only.
Hypothesis 3: The group receiving PAX will be super-
ior to the group receiving PA only.
Methods
Design and setting
The FIX-Heel Trial is designed as a randomised superiority
trial with a three-group parallel design. Reporting of the
protocol follows the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) statement (check-
list uploaded as Additional file 1), TiDieR (Template for
Intervention Description and Replication checklist and
guide) and the Consensus on Exercise Reporting Template
for intervention description [31–33]. The preparation of
the trial, including publishing this trial protocol, was done
in accordance with the PREPARE trial guide [34]. Before
the inclusion of the first participant, the trial was registered
with ClinicalTrials.gov (NCT03804008). Patients will be
recruited from general practice and via social media (see
below). However, for pragmatic reasons, the information
and training instructions will be given at the physiotherapy
department at Aalborg University Hospital, and injections
will be given at a private rheumatology clinic (ReumaNord)
situated in Aalborg, Denmark. Participants will attend the
baseline and 12-week follow-up appointments at the hos-
pital, whereas a link to the questionnaires used will be sent
via REDCap (Vanderbilt University, Nashville, TN, USA) to
participants’ e-mail addresses for the 4-week, 26-week and
52-week follow-ups.
Roles and responsibilities
The project manager is a physiotherapist with 8 years of
experience in treating patients with musculoskeletal
conditions. He will be responsible for recruitment and
analysing data whilst blinded to group allocation. Two
physiotherapists working at the Aalborg University Hos-
pital with 5 and 6 years of experience, respectively, were
recruited and will be responsible for eligibility screening,
delivering interventions and being in contact with partic-
ipants throughout the trial. Before the inclusion of the
first participant, the physiotherapists had received 10
and 19 h of training, respectively, in the procedures of
the trial by the project manager. This includes putting
four pilot study participants through all aspects of the
trial processes. The ultrasound-guided injection will be
performed by a rheumatologist who has more than 15
years of experience with performing ultrasound-guided
injections.
The adaptive recruitment strategy
Participants will primarily be recruited from general
practice, but to ensure that the trial timeline is main-
tained, we will include participants through social media
(Facebook). Initially, we aim to recruit from ten general
practices in the North Denmark Region. We will reach
out to the practices using an open invitation in which
we ask for practices interested in being part of trial
recruitment through the Facebook page of the Center
for General Practice at Aalborg University and through
our network of GPs in the North Denmark Region. If
this is not sufficient, the project manager will contact
general practices directly. The GPs are offered a 30-min
presentation about PF and the trial at their own practice.
If recruitment from general practice is inadequate, we
may employ one of the practices’ secretaries, who exam-
ines the GPs’ daily plans for potential trial participants.
The secretary will then remind the GP of informing the
patient about the trial if the patient is potentially eligible
for inclusion.
General practices will receive an honorarium per pa-
tient they refer to the project manager. It is a standard
honorarium stipulated by the Danish Committee of Mul-
tipractice Studies in General Practice (approximately
€18). Before they agree to participate in recruitment,
they will be informed that they are expected to refer a
minimum of two patients per month. On the basis of
the number of referrals we receive, we will categorise
general practices into three symbolic zones: green,
yellow and red. Practices in the green zone will have
referred a minimum of two patients during the past
month; practices in the yellow zone will only have re-
ferred one patient during the past month; and practices
categorised in the red zone will have failed to refer any
patients during the past month or they will have been in
the yellow zone for two consecutive months. Practices in
the red zone will be contacted by the project manager to
discuss whether other strategies are needed to increase
referrals or if the reason for the lack of referrals is a lack
of potentially eligible participants presenting at the prac-
tice. If half of the clinics are categorised in the red zone
or if less than half of the referred patients are not eligible
during a 2-month period, we will recruit additional gen-
eral practices.
Recruitment through Facebook will be used if fewer
than ten participants have been included during any
given month following referrals from general practices.
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We will post information about the trial on a Facebook
page called ‘Treatment of pains under the foot’ and use
the sponsoring function. We target the sponsoring to-
wards both males and females aged 18 years or older
who are living within an 80-km radius of Aalborg,
Denmark. Each sponsorship will last for 1 week. If this is
not sufficient to achieve at least ten included partici-
pants per month, including those referred from general
practices, we will increase the amount of money per
sponsorship first and increase the radius second. Both
strategies will increase the reach of the sponsorship. We
are able to calculate the cost of each included participant
recruited via Facebook by dividing the cost of 1 week of
sponsoring by the number of participants included
following that week. We have done this before in two
studies to compare the cost of participants from general
practice with participants from Facebook, and partici-
pants recruited from Facebook cost approximately half
that of those from general practice [16, 27].
GPs will invite patients to be included in the trial during
their normal consultations with patients with pain under
the heel. The general practices will send the contact infor-
mation of patients to the project manager, whereas poten-
tial participants recruited through Facebook will contact
the project manager directly. The project manager will then
inform the physiotherapists about the potential participant,
whom they will contact to perform an eligibility telephone
screening. The project manager will have no contact with
participants after he has forwarded the contact details to
the physiotherapists.
Eligibility criteria
The inclusion criteria are as follows: history of inferior
heel pain for at least 3 months before enrolment, pain
on palpation of the medial calcaneal tubercle or the
proximal plantar fascia, thickness of the plantar fascia ≥
4.0 mm, and mean heel pain of ≥ 30 mm on a 100-mm
visual analogue scale (VAS) during the previous week.
The exclusion criteria are as follows: younger than 18
years of age; diabetes; history of inflammatory systemic
diseases (e.g., rheumatoid arthritis or spondyloarthritis)
[19]; prior heel surgery; pregnancy or breastfeeding;
corticosteroid injection specifically for PF within the pre-
vious 6 months; pain or stiffness in the first metatarso-
phalangeal joint to an extent that the exercises cannot
be performed; known hypersensitivity to corticosteroids
or local anaesthetics; skin or soft tissue infection near
the injection site; receipt of any treatment by a health-
care professional for PF within the previous 12 weeks; or
made any substantial changes to usual self-care of the
condition in the last 4 weeks (e.g., started using insoles,
started performing stretching, made a substantial de-
crease in physical activity level). These criteria are in line
with those of similar studies in this patient population
[16, 17, 19]. These criteria lead to a representative sample
of patients with PF because previous studies include the
majority of potentially eligible participants [16, 17, 19].
Randomisation and blinding
Participants will be stratified by sex and block-
randomised in random concealed block sizes of 3 to 12
(1:1:1) in three parallel groups. A researcher not involved
in the trial generated the allocation sequence using a
random number generator on www.sealedenvelope.com
and is the only person who knows the block sizes. The
researcher was trained by the project manager in gener-
ating allocation sequences, and the process was piloted.
The randomisation is coded so that the project manager
does not know which intervention is linked to which
group number (group 1, 2 or 3). The envelopes will be
kept in a locked room at Aalborg University Hospital
where only the two physiotherapists involved in baseline
testing have access. The randomisation schedule was pre-
pared at the Center for General Practice at Aalborg Uni-
versity by a person not involved in the actual trial. The
notes in the envelopes state both group number and inter-
vention, and the physiotherapists responsible for assessing
participants and delivering the interventions will not be
aware of the coding before they open the first envelopes.
In practice, after a participant has been enrolled, has filled
out questionnaires, and has received initial patient advice
and information regarding the practicalities of participa-
tion, the physiotherapist will take an envelope and assign
the participant to the allocated treatment on the basis of
randomisation.
The project manager will be responsible for perform-
ing the statistical analyses and will remain blinded to the
coding until after the analyses have been performed. The
analyses will be performed after the examination that
includes the primary endpoint (the 12-week follow-up)
of the last participant.
Interventions
Patient advice and heel cup
Participants in all three groups will receive the same ini-
tial fundamental patient advice and leaflet about their
condition before randomisation. They receive brief infor-
mation about pathology, risk factors and advice on how
to decrease activities that lead to symptom flares and
slowly progress back to former activity levels guided by
symptoms. To ensure that all participants receive the
exact same information, the physiotherapists read a writ-
ten information out loud; however, they will ask control
questions to clarify if the participants understand the in-
formation and allow participants to pose questions about
the information and participation in general. The leaflet
includes the same information that the physiotherapists
deliver orally after inclusion in the trial.
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Participants will be asked to refrain from seeking other
treatments during the course of the trial. They will be
allowed to self-treat their PF for pain relief (e.g., with ice or
heat packs, rolling a tennis ball under the heel, or massa-
ging the plantar fascia) if they have been doing this for at
least 4 weeks prior to inclusion, but they will not be
encouraged to do so. Participants will be handed a project
diary in which they are asked to record any treatment that
they may have received during the course of the trial,
including any type of self-treatment and use of analgesic or
anti-inflammatory substances. We will inform participants
that follow-up on outcomes is critical, regardless of whether
they comply with their allocated treatment. Two weeks
after inclusion, the physiotherapist who included the par-
ticipant will contact the participant to ask if they have any
questions regarding the condition, the practicalities of
participation, or in relation to performing the exercise
depending on randomisation. If participants have not
achieved a self-evaluated satisfactory result after 12 weeks,
they may discuss other evidence-based treatments (e.g.,
plantar fascia stretching) with the physiotherapist, but they
will be encouraged to continue to comply with their allo-
cated treatment.
We will give all participants a silicone heel cup
(Medi-Dyne Healthcare Products, Colleyville, TX,
USA) for each shoe, and they are advised to use the
heel cups whenever they are wearing shoes. If partici-
pants already use an insole or another type of foot
orthosis, they are allowed to continue wearing this if
they prefer this over the heel cups.
Heavy-slow resistance training
Participants of the PAX and PAXI groups will be
instructed in performing a heel-raise exercise standing
with the forefoot on a step or a book as per Rathleff
et al. [26]. Unlike the pre-determined programme used
in that trial, we will use a self-dosed programme that we
recently found to be associated with the same level of
improvement as the pre-determined programme [16].
Participants will be told that it is important that the
exercise be performed with an adequately heavy load,
and they will be instructed in performing the heel raise
with a load corresponding to an 8 repetition maximum
(RM) (i.e., a weight that can only be lifted eight times).
They may only use a lower relative load if they feel they
are unable to perform the exercise with 8 RM. They
shall perform the exercise for as many sets as possible.
The exercise descriptors are elaborated in Table 1. If
participants feel they are able to perform more than
eight repetitions with only their body mass (8 RM), an
external load consisting of a backpack with books,
weights or water bottles to add weight must be used.
We will tell participants that pain during the exercise is
expected and that there is no upper limit of pain they
are allowed to experience, as long as they feel it is toler-
able. Participants randomised to also receive the injec-
tion will be asked not to perform the exercise within 24
h from the injection and not to progress the method
used to achieve 8 RM until 2 weeks after the injection. If
heel raise without a backpack is sufficient to achieve 8
RM before the injection, participants should not perform
Table 1 Exercise descriptors
1. Load magnitude 8 repetition maximum
2. Number of repetitions ≥ 8 depending on the load
3. Number of sets As many as possible
4. Rest between sets 2 min
5. Number of exercise interventions Every other day
6. Duration of the experimental period 8 weeks
7. Fractional and temporal distribution of
the contraction modes per repetition and
duration (in s) of one repetition
3 s concentric
2 s isometric
3 s eccentric
8. Rest between repetitions No
9. Time under tension 8 s/repetition
≥ 64 s/set
≥ 64 s/training session
10. Volitional muscular failure Yes
11. Range of motion Full range of motion
12. Recovery time between exercise sessions 48 h
13. Anatomical definition of the exercise
(exercise form)
The participant stands with the forefoot on a step. The toes are
maximally dorsally flexed by placing a towel underneath them.
The participant performs a heel raise to maximal plantar flexion
in the ankle joint and afterwards lowers the heel to maximal
dorsal flexion. Supporting oneself for balance by placing the
hands on a wall or a rail is allowed.
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the exercise with a backpack until the third week after
the injection, regardless of any pain reduction following
the injection. They will be told to perform the exercise
until they achieve their Patient Acceptable Symptom
State (PASS) (please see ‘Secondary outcomes’ section
for elaboration) and an additional 4 weeks. To support
the exercise execution, participants receive a written
exercise instruction that also includes pictures of the
exercise (Fig. 1).
Ultrasound-guided corticosteroid injection
Participants randomised to PAXI will receive an ultrasound-
guided corticosteroid injection, preferably within 8 days
from baseline but no later than 14 days after baseline. A 21-
gauge, 40-mm needle is connected to a 2.5-cm3 syringe filled
with 1ml of triamcinolone acetonide 20mg/ml (Trica; Evo-
lan Pharma, Danderyd, Sweden) + 1ml of lidocaine 10mg/
ml (Xylocaine; AstraZeneca, Wilmington, DE, USA). The
skin is cleansed with chlorhexidine alcohol 0.5% (Medic,
Jacksonville, FL, USA). The needle is inserted with a medial
approach under ultrasound guidance aligned with the long
axis of the ultrasound transducer. The injection is distrib-
uted deep and superficially on the plantar fascia surface an-
terior to the insertion on the calcaneal bone in the region of
maximal fascia thickness (see Fig. 2).
Compliance
We will emphasise to participants that we do not know
which of the three groups will be superior and that it is
very important to comply with the group to which they
are allocated for the future results to be meaningful. Par-
ticipants in the PAX and PAXI groups will be told that
complying with the exercise programme is very import-
ant and that exercise compliance is associated with the
odds of their recovery. Complying with the exercise
programme includes performing the exercise with the
prescribed form, contraction time, and sufficient load
and frequency. All participants will be asked to record
their use of the heel cup and any other foot orthoses in
a foot orthoses diary as an estimated percentage of the
time they have worn shoes. In addition, participants per-
forming exercise will receive a training diary in which
they record the number of repetitions and sets and the
date on which the exercise was performed.
Variables
Descriptive
The assessment schedule is found in the SPIRIT figure
(Fig. 3). During the telephone screening and the clinical
examination, we will collect the following data: age,
height, body mass index, location and duration of heel
pain, average heel pain intensity during the past week (0
to 100-mm VAS, where 0 is no pain and 100 is worst
heel pain imaginable), plantar fascia thickness measured
by ultrasonography perpendicular to the calcaneal inser-
tion, presence of palpable pain under the plantar heel,
comorbidity, treatment history, previous care-seeking
behaviour, if females are pregnant or breastfeeding,
number of PF episodes, education level, and work status.
Primary outcome
The primary outcome is the mean pain domain score of
the FHSQ at the 12-week follow-up. The FHSQ is a
questionnaire ranging from 0 (worst possible score) to
100 (best possible score) with high reliability (ICC, 0.74–
0.92) that assesses multiple dimensions of foot-related
health and function and is recommended in this patient
population [35, 36]. The minimal clinically important
difference of the pain domain is 14.1 points [37]. We will
use a Danish validated translation of the original ques-
tionnaire [38].
Secondary outcomes
Secondary outcomes include (1) the other domains of the
FHSQ (function, footwear and general foot health domains),
(2) Global Rating of Change (GROC), (3) PASS, (4) Pain
Fig. 1 Pictures of the exercise participants receive embedded in the written exercise instruction
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Self-Efficacy Questionnaire (PSEQ), and (5) weekly light,
moderate and vigorous physical activity levels.
We will use the GROC to measure participants’ self-
reported improvement on a 7-point Likert scale ranging
from ‘much improved’ to ‘much worse’. Participants are
dichotomised as improved if they rate themselves as
‘much improved’ or ‘improved’ (categories 6 and 7) and
categorised as not improved if they rate themselves from
‘slightly improved’ to ‘much worse’ (categories 1 to 5).
PASS (yes/no) will be used as a measure of when partici-
pants achieve a self-evaluated satisfactory result and feel
no need for further treatment. Therefore, this is not ne-
cessarily a measure of complete recovery, because some
may be satisfied despite still experiencing symptoms.
PASS has been used to evaluate clinically relevant states
in PF and in other musculoskeletal disorders and post-
operative pain [16, 39–41]. Participants will be asked to
report to the physiotherapists as soon as they experience
PASS, and the date will be noted. Furthermore, partici-
pants will be asked about their PASS status during
follow-up. After the participant reports a PASS, they will
be instructed to continue performing the exercise as pre-
scribed for at least 4 weeks. The PSEQ measures pain
self-efficacy and provides a score ranging from 0 (not at
all confident) to 60 (completely confident), with lower
scores indicating lower self-efficacy [42]. The Danish
version of the PSEQ has been validated in a Danish
chronic pain population and has high reliability (ICC,
0.89) [43]. To estimate weekly physical activity level
expressed as metabolic equivalents (METs), we will use
3D accelerometry. Participants will be given a wrist-
worn accelerometer (ActiGraph wGT3X-BT; ActiGraph
LLC, Pensacola, FL, USA) during baseline and will be
asked to wear this during the first 3 weeks after baseline
and then return the accelerometer in a postmarked
envelope. During the 12-week follow-up, participants
receive the accelerometer again and will be wearing it
for an additional 3 weeks before returning it.
Participants will be instructed to wear the accelerometer
at all times. We will use data from the first valid week
recorded during the first and second rounds of wearing
the accelerometer (i.e., 1 week during weeks 1 to 3 and 1
week during weeks 13 to 15). A valid week is defined
as ≥ 4 days of ≥ 10 h of wear time [44]. Data will be
extracted from the accelerometers using the ActiLife
software.
Cost-effectiveness outcomes
A health economic evaluation will be conducted according
to international guidelines [45, 46]. All clinical and cost
data will be collected alongside the trial. A health sector
perspective will be applied to estimate cost utility using
the EuroQol Health Outcome EQ-5D-5L instrument and
the Danish quality-adjusted life-year (QALY) weights to
calculate gained QALYs within a 1-year horizon [47, 48].
For the estimation of patient-specific costs, we will apply
the unique Danish civil registration number for each
participant to combine registrations of all healthcare con-
sumption from 1 year before enrolment to 1-year follow-
up. Data will be taken from the National Patient Register,
the National Health Insurance Register, and the Danish
National Prescription Registry. Productivity costs will be
estimated in a separate analysis measured by a self-
developed questionnaire with questions regarding days of
sick leave and level of productivity. Patients’ co-payments
and other condition-related expenses will also be esti-
mated by using questionnaires during all follow-ups.
Adverse events
Participants will be asked to report any adverse events to
the physiotherapists immediately after they occur by
either telephone, text message or e-mail. Expected ad-
verse events due to the injection are plantar fascia rup-
ture, signs of infection (e.g., fever and local swelling and
redness), and local pain in the area of injection lasting
more than 48 h after injection. Adverse events after the
Fig. 2 Ultrasound image of the calcaneus and the plantar fascia. The stars depict the placement of the injection
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palpation-guided injection are rare, and two trials that
used ultrasound-guided injections reported that no ad-
verse events occurred [19–21]. No stopping rules are
planned. Expected adverse events due to the exercise are
injuries to the musculoskeletal system, such as muscle
tears, muscle strains, a sprained joint, injury from falling
or exacerbation of symptoms related to PF, delayed-
onset muscle soreness equal to or greater than 20mm
on a 0 to 100-mm VAS that lasts for more than 48 h
after performing the exercises, or exacerbation of PF.
Fig. 3 SPIRIT figure. Schedule of enrolment, interventions and assessments
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Adverse events will be graded 1 to 5 according to the
Common Terminology Criteria for Adverse Events v4.03
[49]. A medical doctor specialised in either rheumatol-
ogy or general medicine will assess and grade the ad-
verse event and ultimately make the decision whether
the participant should be withdrawn from the trial due
to the adverse event. If the adverse event is a grade 1
(mild), the participant may be allowed to skip one or
two training sessions without any assessment. If the
adverse event recurs after having skipped the exercise,
the participant will have to be assessed by the medical
doctor before participation in the trial is continued. If a
participant experiences an adverse event and requests
withdrawal from the study, data until the last exercise
activity before the adverse event occurred will be in-
cluded in the analyses. The physiotherapists will report
any incidents to the sponsor as quickly as possible and
no later than 15 days after the participant reported the
event. The sponsor will report any severe adverse events
(grade 3–5) to the Ethics Committee of North Denmark
Region no later than 7 days after being informed. All
adverse events will be reported in the future reporting of
the trial. Any participants who experience harm from
trial participation will receive compensation by the
Patient Compensation Association.
Concurrent observational cohort
Potential participants who are excluded during the phys-
ical examination and eligible participants who decide to
withdraw before randomisation will be asked to be part
of a concurrent observational cohort inspired by the
Spine Patient Outcomes Research Trial [50]. This cohort
will be used to describe how excluded participants fare
and which treatment they seek. If they agree to be in the
cohort, they will receive the same questionnaires as the
participants of the FIX-Heel Trial with the addition of a
questionnaire about care-seeking behaviour and treat-
ments received during the time between the last follow-
up and the current follow-up. We will use the same
follow-up times (4, 12, 26 and 52 weeks) as in the FIX-
Heel Trial; however, all follow-ups will be conducted
through e-mail.
Patient and end-user involvement
To involve both patients and end users in designing the
intervention, the participant leaflet was developed on the
basis of semi-structured interviews with five patients
with PF and five GPs. Patients were asked to describe
their heel pain, how it had affected them and which
topics they felt would be important to include in a leaflet
and in advice to a patient in general. GPs were asked
about their experience with the patient group, which
treatments they would consider and which topics they
felt would be important to include in a leaflet and in
advice to the patient in general. The leaflet and funda-
mental patient advice that the physiotherapists will de-
liver orally to patients are a triangulation of the results
of the interviews with both patients and GPs and recom-
mendations from clinical guidelines and a systematic
review [1, 6, 51].
We will invite representative participants from each
group to be part of the future interpretation of the
results. Their interpretation will be part of the dissemin-
ation of the results in the trial report and during confer-
ences. In practice, we will invite two randomly selected
participants of each group after the primary outcome
has been collected. If a participant declines, we will ran-
domly select a new participant from the same group.
Sample size
The minimal clinically important difference of the FHSQ
pain domain has been found to be either 12.5 or 14.1
points in this patient population [37, 52]. We have
chosen the most conservative option (i.e., 14.1 points) to
form the basis of the sample size calculation. Based on a
standard deviation of 22 points, which is comparable to
the overall standard deviations found in previous studies
of this patient population [19, 53, 54], a two-sided 5%
significance level, and a power of 90%, a sample size of
53 participants in each group will be necessary. Taking
into consideration possible drop-outs, we will include 60
participants in each group, and thus the total sample size
will be 180 participants.
Statistical analyses
All statistical analyses will be performed by a blinded
data analyst according to a pre-established analysis plan
using the intention-to-treat principle. This plan is writ-
ten in consultation with a statistician and will be pub-
lished on the Aalborg University website before the
inclusion of the last participant. SPSS software (IBM
Corporation, Armonk, NY, USA) will be used as statis-
tical software. We will use Q-Q plots and histograms to
assess data normality. Missing outcome data will be im-
puted using multiple imputations based on the values
from previous follow-ups, sex, age, and group allocation.
Primary analysis
The primary analysis will investigate the between-group dif-
ference in FHSQ pain. We will use a linear mixed effects
model with the participant as a random effect, and time (4,
12, 26 and 52weeks), group allocation (PA or PAX or PAXI)
and baseline value as fixed effects. Conclusions will only be
drawn on the basis of the primary endpoint (12 weeks).
Secondary analyses
We will also analyse the mean values of the second-
ary continuous outcomes (other domains of FHSQ,
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PSEQ and physical activity level) using linear mixed
models. The risk difference (¼ Positive outcomes in one groupNumber of participants in group
- Positive outcomes in another groupNumber of participants in group ) will be calculated for the
dichotomised GROC to determine the probability of being
improved, for the PASS (yes/no) to determine the probabil-
ity of achieving a self-evaluated satisfactory result within
the 12, 26 and 52 weeks of intervention. We will also calcu-
late risk differences to determine the probability of experi-
encing a deterioration of PF, defined as a decrease in FHSQ
pain ≥ 14.1 points from one follow-up to another or chan-
ging one’s status from having achieved PASS to no longer
having achieved PASS. We will calculate the number
needed to treat for the primary outcome at the primary
endpoint as 1/risk difference. We will use a Kaplan-Meier
survival analysis and compare survival curves using log-
rank tests to investigate between-group differences in time
to achieving PASS [55, 56]. If a participant changes PASS
multiple times (e.g., achieving PASS before 12 weeks,
reporting not to have achieved PASS at 26 weeks and then
having achieved PASS again at the 52-week follow-up), only
time to the first PASS achieved is used in the analysis.
Cost-effectiveness analysis
The reporting of the economic evaluation will follow the
Consolidated Health Economic Evaluation Reporting
Standards checklist for a more transparent and complete
reporting of methods and findings [57]. For each inter-
vention, mean values (and standard errors of the mean)
will be reported for the main categories of estimated
costs and QALYs, as well as mean differences between
the comparator groups. Probabilistic sensitivity analyses
will be used to estimate the decision uncertainty and cal-
culate incremental cost-effectiveness ratios.
Data monitoring and quality assurance
All data will be stored electronically and are handled ac-
cording to the General Data Protection Regulation. Data
safety may be overseen unannounced by the Danish Data
Protection Agency. Participant data will be stored in RED-
Cap, whereas data processor agreements, collaboration
agreements between the project group and general prac-
tices and protocols will be stored on a secure server at
Aalborg University. To prevent data entry errors, data
collection instruments have been developed in REDCap so
that required data must be included or an error will be
displayed, and validation of each field has been chosen
(e.g., if the format of the data does not appear to be a date
in the field ‘Date’, an error is displayed). Data are checked
once per week by the project manager to ensure there are
no missing data. All data will be kept for 10 years after
completion of the trial in accordance with the European
Code of Conduct for Research Integrity.
Discussion
Future implications
PF is a condition with a wide variety of different treat-
ment options available, with no single treatment show-
ing superiority [18, 51]. HSR is increasingly being used
for rehabilitation of PF, despite its effects having only
been compared with stretching in a single study [26].
Our recent research with HSR for PF shows within-
group improvements in pain similar to those of studies
investigating foot orthoses, corticosteroid injections and
even placebo injections [16]. By comparing HSR with no
HSR and a heel cup and patient advice only, we will be
able to answer if performing exercises is worth the extra
time and effort required from the patient.
Corticosteroid injection may reduce heel pain for up to
1 month, and adverse events are generally rare and have
been reported not to occur when the injection was
performed under ultrasound guidance [19–21]. After 1
month, the improvement in symptoms is similar to that of
placebo. In contrast, the effects of HSR are known for tak-
ing some time to manifest, and performing HSR is usually
painful [16, 17, 26]. Patients ask for both short-term and
long-term pain reduction, and the combination of these
two treatments may potentially offer this. Moreover, in
the qualitative data from our feasibility study, we found
that several participants felt that pain during exercise was
reduced due to the pain relief associated with the injection
[27]. This may improve exercise compliance and overall
improvement. Despite our hypothesis of superiority of
combining the injection with HSR, an injection with cor-
ticosteroid may potentially reduce the effect of HSR. This
would be similar to how corticosteroids reduced the effect
of physiotherapy in a former trial in patients with lateral
elbow tendinopathy. In that trial, corticosteroid injections
and physiotherapy led to a lower rate of successful out-
comes than placebo injections and physiotherapy after 1
year [24]. This indicates that corticosteroids decreased the
effect of physiotherapy. Furthermore, the combination of
exercise and an injection was not superior to an injection
alone in patients with subacromial pain syndrome [29].
One concern is that the pain reduction following the
injection will hamper exercise compliance and affect long-
term outcomes negatively.
The implementation of our findings will be aided by
the inclusion of a cost-effectiveness analysis. There are
obvious differences between treatments in how much
time and materials are required. The treatment offered
in the PA group requires the least, whereas the PAXI
group requires the most. However, this difference may
be equalised by the potential savings on a societal level
in terms of sick leave or on a personal level in terms of
QALYs, condition-related improvement and personal ex-
penses. Any future implementation will also be dependent
on the patients’ experiences and expectations, which is
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why patients are involved in the interpretation of the trial
findings.
Recruiting patients for trials in primary care is a large
challenge, and less than one-third of trials recruit pa-
tients within the original recruitment time frame [58].
We use an adaptive recruitment strategy in which we
focus primarily on recruitment from general practices,
but we will use Facebook recruitment to ensure that the
timeline is kept. We may increase the number of recruit-
ing practices or the area and the money used for spon-
soring Facebook posts, depending on recruitment rate.
This may help inform effective ways of recruiting a large
number of participants from general practice in studies
requiring large numbers of patients.
Strengths
First, the involvement of patients and GPs in developing
the patient advice intervention enables a high level of
acceptability for users. Second, all of the interventions
are within scope, knowledge and skill levels of primary
care clinicians and practices, so they will have a high
feasibility of being implemented, regardless of trial findings.
Third, all potential outcomes of the trial may influence
future clinical practice. If no superiority of one intervention
is found over the others, the minimally invasive or the most
cost-effective should be implemented, depending on patient
preferences. Fourth, to minimise bias, the data analysis will
occur blind to group allocation and will be performed
according to a pre-established and publicly accessible ana-
lysis plan.
Limitations
First, despite the trial being rooted in general practice,
the treatments are delivered at the hospital and at a pri-
vate rheumatology clinic for logistical reasons by physio-
therapists and a rheumatologist. Second, if the PAXI
group is superior to the others, we cannot disregard that
some of that superiority will derive from the placebo
effect of receiving an injection. However, we evaluated
how the relevance of adding a placebo injection to the
PAX group had lessened in light of research concluding
the superiority of corticosteroid injections compared
with placebo [19–21]. Third, we recruit from both gen-
eral practice and from Facebook, and we do not know if
these recruitment sources yield the same type of patient;
still, based on our previous study where we recruited
patients solely via Facebook, three in four will have seen
their GP due to their PF [17]. This may increase the
generalisability of the patients recruited from Facebook
to those seen in general practice.
Trial status
Recruitment was started on January 21, 2019, and the
first participant was included on February 7, 2019. No
amendments have been made to the protocol (version
2.0 January 14, 2019) since it was pre-registered with
ClinicalTrials.gov. When this protocol was submitted for
publication (October 5, 2019), a total of 96 participants
had been included in the trial. We expect recruitment to
be completed in July 2020.
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